Why the study?
Does prior anthracycline therapy lead to progressive deterioration of cardiac function in pediatric oncology patients over a 3-4 year follow-up?
Population
49 pediatric oncology patients, comprising 29 patients with previously detected abnormal systolic function…
Comparison
Prior anthracycline therapy (mean dose 233 mg/m2). vs No prior anthracycline therapy.
Design
Cohort
Follow-up
Mean interval of 43 to 46 months between examinations
Authors
Loading...
Supports non-progressive mild dysfunction post-anthracycline; hypothesis-generating and should not yet change surveillance in pediatric survivors.
Does prior anthracycline therapy lead to progressive deterioration of cardiac function in pediatric oncology patients over a 3-4 year follow-up?
Mildly abnormal cardiac indices detected in children after cessation of anthracycline treatment do not appear to deteriorate over a 3 to 4 year follow-up period.
Li et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: